Menopause at thirty is not a metaphor or hyperbole. POI affects one in a hundred women under forty and one in a thousand under thirty. What happens, why — and what can be done.
In 1942, American gynaecologist Fuller Albright described a phenomenon he then called 'premature menopause'. Young women — some not yet thirty — displayed a hormonal picture typical of the climacteric: elevated FSH, low oestrogen, cessation of menstruation. The nature of the phenomenon remained a mystery for a long time.
Today we know substantially more. The term 'premature menopause' has been replaced in medical practice by 'premature ovarian insufficiency' (POI) — and this is not merely a change of name. Menopause is irreversible. POI is not, or at least not always. Up to ten percent of women diagnosed with POI conceive spontaneously, without treatment. The ovaries continue to function intermittently and unpredictably — and this is precisely what makes POI a medically unique condition.
Premature ovarian insufficiency is the reduction or cessation of ovarian function in women under forty years of age. The diagnosis is established on three criteria:
In the majority of cases — around ninety percent — the cause of POI remains unknown. This does not mean there is none; it means medicine cannot yet identify it with standard methods. Among established causes: genetic factors account for roughly twenty percent of POI cases. The most recognised is fragile X syndrome (FMR1 premutation): carriers have a substantially elevated POI risk. Turner syndrome (monosomy X) and other chromosomal anomalies frequently involve ovarian insufficiency. Autoimmune causes account for about five percent of POI — the immune system attacks the follicular apparatus of the ovary. POI frequently co-occurs with other autoimmune conditions: Addison's disease, autoimmune thyroiditis, type 1 diabetes. Iatrogenic causes: cancer treatment — chemotherapy and radiotherapy — can irreversibly damage follicular reserve. Surgical interventions on the ovaries (cyst removal, endometriomas) also reduce reserve.
Menstrual irregularity is the most obvious symptom, but not the only one. Oestrogen deficiency produces the full spectrum of climacteric symptoms:
Standard investigation when POI is suspected:
Hormone replacement therapy (HRT) is the cornerstone of POI management. The goal is to compensate for oestrogen and progesterone deficiency, protecting bones, heart and nervous system. Standard preparations contain oestradiol (transdermal — the preferred route, bypassing hepatic first-pass metabolism) and micronised progesterone. HRT in POI is used at minimum until the age of natural menopause (around 51), and its risks in young women are incomparably lower than in postmenopausal women.
Fertility and IVF: this is the most painful aspect for most women with POI. With marked ovarian insufficiency, own eggs are generally unavailable — too few follicles, or those present do not respond to stimulation. However, IVF with donor eggs in POI is one of the most successful scenarios in reproductive medicine: the ovaries as such play no role, the uterus functions normally, and implantation rates with donor eggs are high. Up to ten percent of women with POI experience spontaneous pregnancies — this is not zero. Contraception is therefore recommended for women with POI who do not wish to conceive right now, despite cycle irregularities.
On the horizon — experimental therapy: in vitro activation (IVA), in which ovarian tissue is stimulated by biochemical methods, has yielded isolated successful pregnancies. PRP ovarian therapy — intra-ovarian injection of platelet-rich plasma — is under active study but remains experimental, without proven efficacy.
A POI diagnosis is for many women a psychological blow comparable to a loss. Not because the situation is hopeless — options exist. But because the diagnosis arrives unexpectedly, at an age when motherhood seemed simply a matter of timing, and shatters a particular image of the future. Research shows women with POI have significantly elevated rates of anxiety and depression compared with the general population. Psychological support is not a luxury in this diagnosis — it is part of comprehensive patient care.
POI is not menopause, although it resembles it hormonally. It is a condition with heterogeneous causes, unpredictable course and real therapeutic possibilities. HRT protects health. Donor IVF opens the path to pregnancy for most women with POI. Spontaneous pregnancies do occur. And although the diagnosis dismantles expectations, it does not close the door to motherhood — it changes the path to it.